Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350805 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL4858286 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL20570026 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL23926540 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL22749162 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL23567016 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL20570539 | 0.89 | — | — | |
| SCHEMBL20570963 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL22581617 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL4812594 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181576-B1 | METHOD FOR SYNTHESIZING 25-HYDROXY CHOLESTEROL | UNIV ZHEJIANG TECHNOLOGY (CN) | 2019-09-04 | — | — | EP | claimed |
| US-9802977-B2 | Method of synthesizing 25-hydroxy cholesterol | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2017-10-31 | — | — | US | claimed |
| EP-3181576-A1 | METHOD FOR SYNTHESIZING 25-HYDROXY CHOLESTEROL | Zhejiang University of Technology (CN) | 2017-06-21 | — | — | EP | claimed |
| US-20170158729-A1 | METHOD OF SYNTHESIZING 25-HYDROXY CHOLESTEROL | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2017-06-08 | — | — | US | claimed |
| US-12491503-B2 | Hydrogenation process of oxime derivatives | SYNGENTA CROP PROTECTION AG (CH) | 2025-12-09 | — | — | US | disclosed |
| CN-113166183-B | Method for hydrogenating oxime derivatives | 先正达农作物保护股份公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-113195460-B | Enantioselective process | 先正达农作物保护股份公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3877394-B1 | HYDROGENATION PROCESS OF OXIME DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| EP-3877372-B1 | ENANTIOSELECTIVE REDUCTION OF OXIME-DERIVATIVES INVOLVING IRIDIUM BASED CATALYSTS | SYNGENTA CROP PROTECTION AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-3877372-A1 | ENANTIOSELECTIVE PROCESS | Syngenta Crop Protection AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| CN-113195460-A | Enantioselective process | 先正达农作物保护股份公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113166183-A | Process for the hydrogenation of oxime derivatives | 先正达农作物保护股份公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3181576-A1 | METHOD FOR SYNTHESIZING 25-HYDROXY CHOLESTEROL | Zhejiang University of Technology (CN) | 2017-06-21 | — | — | EP | disclosed |
| US-20170158729-A1 | METHOD OF SYNTHESIZING 25-HYDROXY CHOLESTEROL | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2017-06-08 | — | — | US | disclosed |
| EP-2043611-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | Nucryst Pharmaceuticals Corp. (CA) | 2009-04-08 | — | — | EP | disclosed |
| US-20080050452-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-28 | — | — | US | disclosed |
| US-20080044491-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-21 | — | — | US | disclosed |
| US-20080014278-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| US-20080014247-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| WO-2008005705-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS CORP. (CA) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158729-A1 | METHOD OF SYNTHESIZING 25-HYDROXY CHOLESTEROL | CYP46A1, HMGCR, DHCR7 | KDM4E 1418/4885CYP3A4 76/4885CA1 454/4885 |
| US-12491503-B2 | Hydrogenation process of oxime derivatives | HMOX2, HAO2, PRDX5 | KDM4E 1418/4885CYP3A4 186/4885CA1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.